Extensive prior efforts by our group to develop a therapeutic antibody targeting FGL2 failed to prevent recurrence—the primary cause of brain tumor–associated death (https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018204928). The gene discussed is FGL2; the disease is brain neoplasm.